Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2002 1
2003 1
2004 1
2007 1
2012 1
2013 1
2014 1
2015 1
2018 1
2019 1
2020 1
2021 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Breast-cancer risk in families with mutations in PALB2.
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E, Neuhausen SL, Teo ZL, Khan S, Aittomäki K, Moilanen JS, Turnbull C, Seal S, Mannermaa A, Kallioniemi A, Lindeman GJ, Buys SS, Andrulis IL, Radice P, Tondini C, Manoukian S, Toland AE, Miron P, Weitzel JN, Domchek SM, Poppe B, Claes KB, Yannoukakos D, Concannon P, Bernstein JL, James PA, Easton DF, Goldgar DE, Hopper JL, Rahman N, Peterlongo P, Nevanlinna H, King MC, Couch FJ, Southey MC, Winqvist R, Foulkes WD, Tischkowitz M. Antoniou AC, et al. N Engl J Med. 2014 Aug 7;371(6):497-506. doi: 10.1056/NEJMoa1400382. N Engl J Med. 2014. PMID: 25099575 Free PMC article.
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Carrier M, et al. N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4. N Engl J Med. 2019. PMID: 30511879 Clinical Trial.
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM. Stewart DJ, et al. Cancer Treat Rev. 2007 Apr;33(2):101-37. doi: 10.1016/j.ctrv.2006.12.002. Epub 2007 Feb 5. Cancer Treat Rev. 2007. PMID: 17276603 Review.
Based on this and other clinical observations, we hypothesize: (1) active resistance may modulate cell killing at lower doses, but ability to overcome this by increasing doses is limited by saturable passive resistance (e.g. by non-cycling cells). (2) Cells surviving initi …
Based on this and other clinical observations, we hypothesize: (1) active resistance may modulate cell killing at lower doses, but ability t …
Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study.
Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ; EORTC. Therasse P, et al. J Clin Oncol. 2003 Mar 1;21(5):843-50. doi: 10.1200/JCO.2003.05.135. J Clin Oncol. 2003. PMID: 12610183 Review.
PATIENTS AND METHODS: Locally advanced breast cancer patients were randomly assigned onto a study comparing cyclophosphamide (C; 75 mg/m(2) orally days 1 to 14), epirubicin (E; 60 mg/m(2) intravenously [IV] days 1, 8), and fluorouracil (F; 500 mg/m(2) IV days 1, 8) six cyc …
PATIENTS AND METHODS: Locally advanced breast cancer patients were randomly assigned onto a study comparing cyclophosphamide (C; 75 mg/m(2) …
Implementation of Competency-Based Medical Education in a Canadian Medical Oncology Training Program: a First Year Retrospective Review.
Tomiak A, Linford G, McDonald M, Willms J, Hammad N. Tomiak A, et al. J Cancer Educ. 2022 Jun;37(3):852-856. doi: 10.1007/s13187-020-01895-y. Epub 2020 Oct 27. J Cancer Educ. 2022. PMID: 33108804
These centered on (1) faculty and resident development and engagement; (2) sharing the work of CBME; (3) collaboration and communication; (4) global assessment; (5) assessment plan challenges; (6) burden of CBME; (7) limitations of e-portfolio; (8) importance of early trac …
These centered on (1) faculty and resident development and engagement; (2) sharing the work of CBME; (3) collaboration and communication; (4 …
Expandable Graphite as a Multifunctional Flame-Retarding Additive for Highly Filled Thermal Conductive Polymer Formulations.
Tomiak F, Schneider K, Schoeffel A, Rathberger K, Drummer D. Tomiak F, et al. Polymers (Basel). 2022 Apr 15;14(8):1613. doi: 10.3390/polym14081613. Polymers (Basel). 2022. PMID: 35458364 Free PMC article.
Good thermal conductivity properties are proven to be particularly effective in test scenarios where the heat impact is comparatively low and the testing environment provides good heat dissipation and convective cooling possibilities. For candle-like ignition scenarios (e. …
Good thermal conductivity properties are proven to be particularly effective in test scenarios where the heat impact is comparatively low an …
Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study.
Krzemień P, Kasperczyk S, Banach M, Kasperczyk A, Dobrakowski M, Tomasik T, Windak A, Mastej M, Catapano A, Ray KK, Mikhailidis DP, Toth PP, Howard G, Lip GYH, Tomaszewski M, Charchar FJ, Sattar N, Williams B, MacDonald TM, Penson PE, Jóźwiak JJ; LIPIDOGRAM2015 Investigators. Krzemień P, et al. Rheumatol Int. 2022 Feb;42(2):261-271. doi: 10.1007/s00296-021-05033-9. Epub 2021 Nov 10. Rheumatol Int. 2022. PMID: 34755204 Free PMC article.
Intra-crystalline protein diagenesis (IcPD) in Patella vulgata. Part II: Breakdown and temperature sensitivity.
Demarchi B, Collins MJ, Tomiak PJ, Davies BJ, Penkman KE. Demarchi B, et al. Quat Geochronol. 2013 Apr;16(100):158-172. doi: 10.1016/j.quageo.2012.08.001. Quat Geochronol. 2013. PMID: 23956808 Free PMC article.
The patterns of diagenesis are complex; therefore the kinetic parameters of the main reactions were estimated by two different methods: 1) a well-established approach based on fitting mathematical expressions to the experimental data, e.g. first-order rate equations for hy …
The patterns of diagenesis are complex; therefore the kinetic parameters of the main reactions were estimated by two different methods: 1) a …
Incident Vertebral Fractures in Children With Leukemia During the Four Years Following Diagnosis.
Cummings EA, Ma J, Fernandez CV, Halton J, Alos N, Miettunen PM, Jaremko JL, Ho J, Shenouda N, Matzinger MA, Lentle B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lang B, Israels S, Grant RM, Couch R, Barr R, Hay J, Rauch F, Siminoski K, Ward LM; Canadian STOPP Consortium (National Pediatric Bone Health Working Group). Cummings EA, et al. J Clin Endocrinol Metab. 2015 Sep;100(9):3408-17. doi: 10.1210/JC.2015-2176. Epub 2015 Jul 14. J Clin Endocrinol Metab. 2015. PMID: 26171800 Free PMC article.
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Piccart MJ, Bruning P, Wildiers J, Awada A, Schornagel JH, Thomas J, Tomiak E, Bartholomeus S, Witteveen PO, Paridaens R. Piccart MJ, et al. Ann Oncol. 1995 Sep;6(7):673-7. doi: 10.1093/oxfordjournals.annonc.a059283. Ann Oncol. 1995. PMID: 8664188 Free article. Clinical Trial.
BACKGROUND: In an attempt to increase chemotherapy dose intensity by step-wise reduction of the time interval between treatment cycles, filgrastim was administered to breast cancer patients receiving a three-month combination chemotherapy with epirubicin (E) and cyclophosp …
BACKGROUND: In an attempt to increase chemotherapy dose intensity by step-wise reduction of the time interval between treatment cycles, filg …
13 results